EXACT Therapeutics AS: Primary insider notification

13 Jun 2025 12:09 CEST

In connection with the re-election of Jonathan Allis to the board of directors
of EXACT Therapeutics AS ("EXACT-Tx" or the "Company"), Jonathan Allis has been
granted 569,370 options in the Company which will vest on a quarterly basis.
With the addition of the 63,263 options previously granted, Mr. Allis now has a
total of 632,633 options.
Please see the attached notification form for further information.

This information is subject to the disclosure requirements in section 5-12 of
the Norwegian Securities Trading Act.

For more information, please contact:
Per Walday, CEO
EXACT Therapeutics
Email per.walday@exact-tx.com

About EXACT-Tx:
EXACT-Tx is a clinical-stage precision medicine company utilizing the power of
ultrasound and microbubbles to enable targeted drug delivery in oncology.
Acoustic Cluster Therapy (ACT®) follows a unique approach and may be applied to
a wide range of therapeutic agents across a multitude of indications including
within oncology (chemotherapy, immunotherapy) and brain diseases.
www.exact-tx.com

More information:
Access the news on Oslo Bors NewsWeb site

649110_Notification of transactions by Primary Insiders (grant options).pdf